Morgan Stanley’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-429,340
| Closed | -$4.28M | – | 8262 |
|
|
2025
Q2 | $4.28M | Buy |
429,340
+178,209
| +71% | +$1.44M | ﹤0.01% | 4182 |
|
|
2025
Q1 | $1.5M | Buy |
251,131
+514
| +0.2% | +$3.77K | ﹤0.01% | 4784 |
|
|
2024
Q4 | $1.92M | Sell |
250,617
-250,749
| -50% | -$2.15M | ﹤0.01% | 4721 |
|
|
2024
Q3 | $5.12M | Sell |
501,366
-587,933
| -54% | -$8.97M | ﹤0.01% | 3945 |
|
|
2024
Q2 | $16.2M | Sell |
1,089,299
-543,057
| -33% | -$7.78M | ﹤0.01% | 2892 |
|
|
2024
Q1 | $22.3M | Sell |
1,632,356
-630,630
| -28% | -$6.87M | ﹤0.01% | 2577 |
|
|
2023
Q4 | $24.8M | Buy |
2,262,986
+2,001,233
| +765% | +$19.8M | ﹤0.01% | 3142 |
|
|
2023
Q3 | $2.87M | Buy |
261,753
+85,073
| +48% | +$1.09M | ﹤0.01% | 4138 |
|
|
2023
Q2 | $2.34M | Sell |
176,680
-386,534
| -69% | -$5.51M | ﹤0.01% | 4319 |
|
|
2023
Q1 | $7.67M | Sell |
563,214
-283,645
| -33% | -$5.08M | ﹤0.01% | 3389 |
|
|
2022
Q4 | $16.5M | Buy |
846,859
+12,965
| +2% | +$253K | ﹤0.01% | 2539 |
|
|
2022
Q3 | $15.9M | Sell |
833,894
-219,340
| -21% | -$5.05M | ﹤0.01% | 2452 |
|
|
2022
Q2 | $21.7M | Buy |
1,053,234
+250,864
| +31% | +$5.95M | ﹤0.01% | 2199 |
|
|
2022
Q1 | $25.8M | Buy |
802,370
+638,371
| +389% | +$23.2M | ﹤0.01% | 1853 |
|
|
2021
Q4 | $7.64M | Buy |
163,999
+7,391
| +5% | +$246K | ﹤0.01% | 3249 |
|
|
2021
Q3 | $4.23M | Buy |
156,608
+65,256
| +71% | +$1.71M | ﹤0.01% | 3911 |
|
|
2021
Q2 | $2.34M | Buy |
91,352
+91,206
| +62,470% | +$2.17M | ﹤0.01% | 4509 |
|
|
2021
Q1 | $5K | Sell |
146
-8,307
| -98% | -$300K | ﹤0.01% | 7105 |
|
|
2020
Q4 | $286K | Buy |
8,453
+6,078
| +256% | +$161K | ﹤0.01% | 5402 |
|
|
2020
Q3 | $59K | Buy |
+2,375
| New | +$63.9K | ﹤0.01% | 5664 |
|
Other funds holding ITOS
Morgan Stanley's ITOS Position: Q3 2025 in Review
Morgan Stanley sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 429,340 shares — an estimated $4.28M sold.
Morgan Stanley first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $25.8M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Morgan Stanley reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Morgan Stanley sold 429,340 iTeos Therapeutics shares in Q3 2025, an estimated $4.28M.
- Morgan Stanley first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Morgan Stanley's iTeos Therapeutics position peaked at $25.8M in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.